Aspirin resistance: review of possible mechanisms

  • В. В. Джаши Moscow Medical Academy named after I.M. Sechenov, Moscow, Russia
Keywords: antiplatelet therapy, aspirin, resistance, mechanism of resistance


Antiplatelet therapy is cornerstone of cardiovascular medicine and aspirin is a basic drug from this pharmacol¬ogical group. Despite its proven clinical efficacy in both the primary and secondary prevention of myocardial infarc¬tion, stroke and cardiovascular death patients taking aspirin continue to suffer complications. The mechanisms of resistance are still not well understood, but there are various clinical, biological and genetic factors which can con¬tribute to this phenomenon. They range from non-compliance to genetic polymorphism. Further studies are still re¬quired in order to be aware of the exact mechanisms of aspirin resistance and develop new treatment strategies, thus improving disease management of millions of patients. In this paper we presented an overview of possible mecha¬nisms .


Antiplatelet Trialists’ collaboration. Collaborative overview of randomized trials of Antiplatelet therapy—I: prevention of death, myocardial infarction, and stroke by prolonged Antiplatelet therapy in various categories of patients. BMJ.1994; 308:81-106.

ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction:ISIS-2. Lancet. 1988;2:349-360.

Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomized trials of Antiplatelet ther¬apy for prevention of death, myocardial infarction and stroke in high risk patients. BMJ 2002;324,71-86.

Grotemeyer KH, Scharafinski HW, Husstedt IW. Two- year follow-up of aspirin responder and aspirin non¬responders. A pilot-study including 180 post-stroke patients. Thromb Res. 1993;71(5):397-403.

Grundmann K, Jaschonek K, Kleine B, Dichgans J, Topka H. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol. 2003;250 (1):63-6.

Mueller MR, Salat A, Stangl P, Murabito M, Pulaki S, et al. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost. 1997;78(3):1003-7.

Gum PA, Kottke-Marchant K, Welsh PA, White J, To¬pol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable pa¬tients with cardiovascular disease. J Am Coll Cardiol. 2003;41(6):961-5.

Christopher P. Martin, Robert L. Talbert. Aspirin Resis¬tance: An evaluation of Current Evidence and Measure¬ment Methods. Pharmacotherapy. 2005; 25(7):942-953.

Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet. 2006;367(9510):606-17.

Topol EJ, Easton D, Harrington RA, Amarenco P, Califf RM, Graffagnino C, Davis S, Diener H-C, Ferguson J, Fitzgerald D, Granett J, Shuaib A, Koudstaal PJ, Ther¬oux P, Van de Werf F, Sigmon K, Pieper K, Vallee M, Willerson JT. Randomized, double-blind, placebo- controlled, international trial of the oral IIb/IIIa antago¬nist lotrafiban in coronary and cerebrovascular disease. Circulation 2003;108:399-406.

Bhatt DL, Chew DP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery .Circulation 2001;103:363-368.

Chen W-H, Lee PY, Ng W, Yat-Yin Kwok J, Cheng X, Tse HF, Lau CP.Prevalence, profile, and predictors of aspirin resistance measured by the Ultegra rapid platelet function assay-ASA in patients with coronary artery disease. J Am Coll Cardiol 2005;45:382A.

Bhatt DL, Topol EJ. Antiplatelet and anticoagulant ther¬apy in the secondary prevention of ischemic heart dis¬ease. Med Clin North Am 2000;84:163-179.

J.C.Hostetter, D.L.Bhatt. The expanding role of Anti¬platelet agents in coronary artery disease. Minerva Car- dioangiol 2003; 51:531-46.

MacDonald TM, Wei L. Effect of ibuprofen on cardio- protecive effect os aspirin. Lancet 2003; 361:573-4.

Hurlen M, Seljeflot I, Arnesen H. Increased platelet aggregability during exercise in patients with previous myocardial infarction. Lack of inhibition by aspirin. Thromb Res. 2000;99(5):487-94.

Pulcinelli FM, Pignatelli P, Celestini A, Riondino S, Gazzaniga PP, Violi F. Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients. J Am Coll Cardiol. 2004;43(6):979-84.

Cipollone F, Rocca B, Patrono C. Ciclooxygenase-2 expression and inhibition in atherothrombosis. Arterio- scler Thromb Vasc Biol. 2004;24(2):246-55.

Newman PJ, Derbes RS, Aster RH. The human platelet alloantigens PLA1 and PLA2 are associated with a leu- cine3 3/proline33 amino acid polymorphism in mem¬brane glycoprotein IIIa, and are distinguishable by DNA typing. J Clin Invest 1989;83:778-81.

Helgason CM et al. (1994) Development of aspirin re¬sistance in persons with previous ischemic stroke. Stroke 25: 2331-2336.

Cotter G, Shemesh E, Zehavi M, Dinur I, Rudnick A, Milo O, et al. Lack of aspirin effect: aspirin resistance or resistance to taking aspirin? Am Heart J. 2004;147 (2):293-300.

Ray WA, Stein CM, Hall K, Daugherty JR, Griffin MR. Nonsteroidal anti-inflammatory drugs and risk of seri¬ous coronary heart disease: an observational cohort study. Lancet 2002;359:118-23.

Livio V, Delmaschio A, Cerletti C, deGaetano G. Indo- methacin prevents long-lasting inhibitory effects of aspirin on human platelet cyclooxygenase. Prostagland¬ins 1982; 23:787-96.

Cipollone F, Rocca B, Patrono C. Ciclooxygenase-2 expression and inhibition in atherothrombosis. Arterio- scler Thromb Vasc Biol. 2004;24(2):246-55.

Patrono C, Coller B, Dalen JE, FitzGerald GA, Fuster V, Gent M, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest. 2001;119(1 suppl.):39S-63S.

Zimmerman N, Wenk A, Kim U, et al. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation 2003;108:542-7.

Kawasaki T, Ozeki Y, Igawa T, Kambayashi J. In¬creased platelet sensitivity to collagen in individuals resistant to low-dose aspirin. Stroke 2000;31:591-5.

Weber AA, Zimmerman KC, Meyer-Kirchrath J, Schoer K. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet 1999;353:900.

How to Cite
Джаши, В. (2018). Aspirin resistance: review of possible mechanisms. Bulletin of the International Scientific Surgical Association, 2(2-3), 45-48. Retrieved from
Original Articles